Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.62 |
| ▸ | CA1 | P00915 | 15/20 | 0.62 |
| ▸ | CA9 | Q16790 | 11/20 | 0.62 |
| ▸ | CA7 | P43166 | 6/20 | 0.62 |
| ▸ | CA12 | O43570 | 6/20 | 0.62 |
| ▸ | CA4 | P22748 | 4/20 | 0.62 |
| ▸ | CA6 | P23280 | 4/20 | 0.62 |
| ▸ | CA5A | P35218 | 4/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.62 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13612757 | 0.81 | CA1 (0.41) | CA2CA1CA9CA7CA12 | |
| SCHEMBL793608 | 0.80 | CA2 (0.69) | CA2CA1CA9CA7CA12 | |
| SCHEMBL709850 | 0.79 | LMNA (0.50) | CA2CA1CA9LMNA | |
| SCHEMBL248783 | 0.77 | CA1 (1.00) | CA2CA1CA9CA7CA12 | |
| SCHEMBL1803937 | 0.77 | PTGS1 (0.66) | CA2CA1CA9CA7CA12 | |
| SCHEMBL29906360 | 0.77 | CA1 (1.00) | CA2CA1CA9CA7CA12 | |
| SCHEMBL1803934 | 0.77 | CA2 (0.64) | CA2CA1CA9CA7CA12 | |
| SCHEMBL2517351 | 0.77 | CA2 (0.64) | CA2CA1CA9CA7CA12 | |
| SCHEMBL3783116 | 0.77 | CA2 (0.59) | CA2CA1CA9CA7CA12 | |
| SCHEMBL1802515 | 0.76 | CA2 (0.58) | CA2CA1CA9CA7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| EP-1611091-B1 | Substituted phenylalkanoic acid derivatives and their use for respiratory disease treatment | ASTRAZENECA AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| CN-100575330-C | Novel compounds | ASTRAZENECA AB | 2009-12-30 | — | — | CN | disclosed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
| CN-1791572-A | Novel compounds | ASTRAZENECA AB (SE) | 2006-06-21 | — | — | CN | disclosed |
| EP-1611091-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089885-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166117-A1 | Novel Compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | CA2 168/4885CA1 2232/4885CA9 484/4885 |
| US-20060264435-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | CA2 168/4885CA1 2232/4885CA9 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.